Compensatory mutations in the tyrosine kinase domain of EGFR or the constitutively active and truncated form of EGFR (i.e. EGFRvIII) are shown to predict response to anti-EGFR therapy in other tumor types[13,14,21,22]. Here, EGFR is linked to neoplasm.